Global Schizophrenia Market

Schizophrenia Market by Types (Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, and Others), Diagnosis (Physical Examination, Psychiatric Evaluation, and Tests & Screenings), Treatments (First-generation Antipsychotics, Second-generation Antipsychotics, Third-generation Antipsychotics, Psychotherapies, and Other Therapeutic Drugs), Routes of Administrations (Injectables and Oral), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030

  • Report ID: HC-4239
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 170
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global schizophrenia market size was valued at around USD 7,666 million in 2021 and is anticipated to reach USD 11,056 million by 2030, expanding at a CAGR of around 4.1% during the forecast period, 2022 – 2030. The growth of the market is attributed to the rising cases of schizophrenia around the globe.

Global Schizophrenia Market Outlook

The World Health Organization (WHO) describes schizophrenia as substantial impairments in the way reality is perceived by individuals. It is considered as a chronic and serious mental disorder in which individuals interpret reality in abnormal way. It affects thoughts, behavior, and feelings of an individual. An individual suffering from schizophrenia had difficulties between reality and fantasy. Some of the symptoms of Schizophrenia includes delusions, hallucinations, social withdrawal, difficulty in paying attention, and others.

Psychiatrists and psychologists diagnose schizophrenia with blood tests, MRI scans, physical tests, psychiatric evaluations, and others. After the diagnosis, psychiatrists suggest methods of treatment for the disease. Individua suffering from schizophrenia require lifelong treatment. The treatment methods include different types of psychotherapies including cognitive behavior therapy, individual therapy, social skills training, and others, medication such as second-generation antipsychotics, and other therapeutic drugs. Early diagnosis and treatment aid individuals to get symptoms of the disease under control before any serious complications arise and to improve the long-term outlook.

Market Trends, Drivers, Restraints, and Opportunities

  • Rapidly changing lifestyle is expected to drive the global schizophrenia market during the forecast period.
  • Increasing consumption of alcohol, narcotics, and others is anticipated to boost the market in the coming years.
  • Increasing expenditure and investments in mental health spurs the market.
  • Surging chronic ailments around the globe are expected to drive the market during the projected period.
  • Lack of awareness regarding schizophrenia in developing countries is anticipated to hamper the growth of the market during the forecast period.
  • High cost of treatments for schizophrenia restrains the market.
  • Growing demand for improved healthcare infrastructure and services offer growth opportunities to the key market players.

Scope of the Report

The report on the global schizophrenia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Schizophrenia Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2021

Historic Data

2019–2020

Forecast Period

2022–2030

Segmentation

Types (Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, and Others), Diagnosis (Physical Examination, Psychiatric Evaluation, and Tests & Screenings), Treatments (First-generation Antipsychotics, Second-generation Antipsychotics, Third-generation Antipsychotics, Psychotherapies, and Other Therapeutic Drugs), and Routes of Administrations (Injectables and Oral)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Mayo Foundation for Medical Education and Research (MFMER); Allergan, Plc; Novartis AG; PsychoGenics, Inc.; Merz Pharma GmbH & Co.; and Others

Market Segment Insights

Paranoid schizophrenia drives the market

Based on types, the market is divided into catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. The paranoid schizophrenia segment is expected to boost the market during the forecast period, as it is considered as a common type of schizophrenia. Changing lifestyle, growing stress, and increasing cases of drug abuse aid in the expansion of the segment.

Global Schizophrenia Market by Types

Psychiatric evaluation segment boosts the market

In terms of diagnosis, the market is segregated into physical examination, psychiatric evaluation, and tests & screenings. The psychiatric evaluation segment is projected to drive the market during the forecast period, as it is considered as a reliable method to diagnose schizophrenia. Through psychiatric evaluation, doctors observe patients for symptoms for schizophrenia such as hallucinations, delusions, catatonic behavior, disorganized speech, and negative symptoms such as lack of pleasure, withdrawal, diminished emotional expression, and others.

Second-generation antipsychotics segment holds a key market share

On the basis of treatments, the market is divided into first-generation antipsychotics, second-generation antipsychotics, third-generation antipsychotics, psychotherapies, and other therapeutic drugs. The second-generation antipsychotics segment is estimated to expand at a significant pace during the forecast period, as they are considered to aid in curing some or all of the symptoms of schizophrenia. The second-generation antipsychotic drugs such as Risperdal (Risperidone), Seroquel (Quetiapine), Zyprexa (Olanzapine), Geodon (Ziprasidone), and others are commonly prescribed by doctors to treat schizophrenia.

Global Schizophrenia Market by Treatments

Injectables segment expands rapidly

In terms of routes of administrations, the market is bifurcated into injectables and oral. The injectable segment is projected to fuel the market during the forecast period, owing to its high efficiency and lower chances of hospitalization. Continuous advancements in treatment methods aids in the expansion of the segment. The oral segment is anticipated to boost the market during the forecast period, as they are considered as the first-line of treatment for schizophrenia, and they are easily available.

North America dominates the market

Based on regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to register a significant CAGR during the forecast period, due to increasing cases of schizophrenia and rising demand for treatment for schizophrenia in the region. Growing geriatric population, advanced medical care, and early treatment capabilities aid in the expansion of the market in North America. Rising population and increasing cases of mental illness in countries such as Singapore, Japan, and Hong Kong are anticipated to drive the market in Asia Pacific in the coming years.

Global Schizophrenia Market by Regions

Segments

The global schizophrenia market has been segmented on the basis of

Types
  • Catatonic Schizophrenia
  • Paranoid Schizophrenia
  • Undifferentiated Schizophrenia
  • Hebephrenic Schizophrenia
  • Residual Schizophrenia
  • Others
Diagnosis
  • Physical Examination
  • Psychiatric Evaluation
  • Tests & Screenings
Treatments
  • First-generation Antipsychotics
  • Second-generation Antipsychotics
  • Third-generation Antipsychotics
  • Psychotherapies
  • Other Therapeutic Drugs
Routes of Administrations
  • Injectables
  • Oral
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Johnson & Johnson Services, Inc.
  • Karuna Therapeutics
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Otsuka Holdings Co., Ltd.
  • Alkermes
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Mayo Foundation for Medical Education and Research (MFMER)
  • Allergan, Plc
  • Novartis AG
  • PsychoGenics, Inc.
  • Merz Pharma GmbH & Co.
  • Others

Competitive Landscape

The schizophrenia market is competitive with the presence of key players such as Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Mayo Foundation for Medical Education and Research (MFMER); Allergan, Plc; Novartis AG; PsychoGenics, Inc.; Merz Pharma GmbH & Co.; and others, who use strategies such as product launches, mergers, collaborations, partnerships, and acquisitions to strengthen their hold on the market. For example, in June 2020, announced the positive outcome of meeting with the US Food and Drug Administration (FDA) for its product KarXT, which works as an Acute Psychosis treatment for patients suffering from schizophrenia. In November 2020, Johnson & Johnson Services, Inc. submitted a supplemental new drug application for paliperidone palmitate to the US FDA.

Global Schizophrenia Market by Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Schizophrenia Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Schizophrenia Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Schizophrenia Market - Supply Chain
  4.5. Global Schizophrenia Market Forecast
     4.5.1. Schizophrenia Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Schizophrenia Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Schizophrenia Market Absolute $ Opportunity
5. Global Schizophrenia Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Schizophrenia Market Size and Volume Forecast by Types
     5.3.1. Catatonic Schizophrenia
     5.3.2. Paranoid Schizophrenia
     5.3.3. Undifferentiated Schizophrenia
     5.3.4. Hebephrenic Schizophrenia
     5.3.5. Residual Schizophrenia
     5.3.6. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Schizophrenia Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Schizophrenia Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Schizophrenia Demand Share Forecast, 2019-2026
7. North America Schizophrenia Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Schizophrenia Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Schizophrenia Market Size and Volume Forecast by Types
     7.4.1. Catatonic Schizophrenia
     7.4.2. Paranoid Schizophrenia
     7.4.3. Undifferentiated Schizophrenia
     7.4.4. Hebephrenic Schizophrenia
     7.4.5. Residual Schizophrenia
     7.4.6. Others
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Schizophrenia Demand Share Forecast, 2019-2026
8. Latin America Schizophrenia Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Schizophrenia Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Schizophrenia Market Size and Volume Forecast by Types
     8.4.1. Catatonic Schizophrenia
     8.4.2. Paranoid Schizophrenia
     8.4.3. Undifferentiated Schizophrenia
     8.4.4. Hebephrenic Schizophrenia
     8.4.5. Residual Schizophrenia
     8.4.6. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Schizophrenia Demand Share Forecast, 2019-2026
9. Europe Schizophrenia Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Schizophrenia Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Schizophrenia Market Size and Volume Forecast by Types
     9.4.1. Catatonic Schizophrenia
     9.4.2. Paranoid Schizophrenia
     9.4.3. Undifferentiated Schizophrenia
     9.4.4. Hebephrenic Schizophrenia
     9.4.5. Residual Schizophrenia
     9.4.6. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Schizophrenia Demand Share Forecast, 2019-2026
10. Asia Pacific Schizophrenia Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Schizophrenia Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Schizophrenia Market Size and Volume Forecast by Types
     10.4.1. Catatonic Schizophrenia
     10.4.2. Paranoid Schizophrenia
     10.4.3. Undifferentiated Schizophrenia
     10.4.4. Hebephrenic Schizophrenia
     10.4.5. Residual Schizophrenia
     10.4.6. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Schizophrenia Demand Share Forecast, 2019-2026
11. Middle East & Africa Schizophrenia Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Schizophrenia Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Schizophrenia Market Size and Volume Forecast by Types
     11.4.1. Catatonic Schizophrenia
     11.4.2. Paranoid Schizophrenia
     11.4.3. Undifferentiated Schizophrenia
     11.4.4. Hebephrenic Schizophrenia
     11.4.5. Residual Schizophrenia
     11.4.6. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Schizophrenia Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Schizophrenia Market: Market Share Analysis
  12.2. Schizophrenia Distributors and Customers
  12.3. Schizophrenia Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Johnson & Johnson Services, Inc.
     12.4.2. Karuna Therapeutics
     12.4.3. Bristol-Myers Squibb Company
     12.4.4. AstraZeneca
     12.4.5. Otsuka Holdings Co., Ltd.
     12.4.6. Alkermes
     12.4.7. Eli Lilly and Company
     12.4.8. Pfizer, Inc.
     12.4.9. Sumitomo Dainippon Pharma Co., Ltd.
     12.4.10. Mayo Foundation for Medical Education and Research (MFMER)&a
The global schizophrenia market has been segmented on the basis of

Types
  • Catatonic Schizophrenia
  • Paranoid Schizophrenia
  • Undifferentiated Schizophrenia
  • Hebephrenic Schizophrenia
  • Residual Schizophrenia
  • Others
Diagnosis
  • Physical Examination
  • Psychiatric Evaluation
  • Tests & Screenings
Treatments
  • First-generation Antipsychotics
  • Second-generation Antipsychotics
  • Third-generation Antipsychotics
  • Psychotherapies
  • Other Therapeutic Drugs
Routes of Administrations
  • Injectables
  • Oral
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Johnson & Johnson Services, Inc.
  • Karuna Therapeutics
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Otsuka Holdings Co., Ltd.
  • Alkermes
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Mayo Foundation for Medical Education and Research (MFMER)
  • Allergan, Plc
  • Novartis AG
  • PsychoGenics, Inc.
  • Merz Pharma GmbH & Co.
  • Others

The schizophrenia market is competitive with the presence of key players such as Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Mayo Foundation for Medical Education and Research (MFMER); Allergan, Plc; Novartis AG; PsychoGenics, Inc.; Merz Pharma GmbH & Co.; and others, who use strategies such as product launches, mergers, collaborations, partnerships, and acquisitions to strengthen their hold on the market. For example, in June 2020, announced the positive outcome of meeting with the US Food and Drug Administration (FDA) for its product KarXT, which works as an Acute Psychosis treatment for patients suffering from schizophrenia. In November 2020, Johnson & Johnson Services, Inc. submitted a supplemental new drug application for paliperidone palmitate to the US FDA.

Global Schizophrenia Market by Key Players

Buy Report

FAQ Section

Some frequently asked quetions about this report!

The market is estimated to register CAGR of around 4.1% during the forecast period.

The global schizophrenia market size was valued at around USD 7,666 million in 2021 and is anticipated to reach around USD 11,056 million by 2030.

Catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, and residual schizophrenia are some of the types of schizophrenia.

Schizophrenia is considered as a chronic and serious mental disorder in which individuals interpret reality in abnormal way.

North America dominates the global schizophrenia market.

Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; and Sumitomo Dainippon Pharma Co. are some of the key players in the market.